Clinical Cell Culture

Shares in Avita Medical have hit a 2014 low following the company’s announcement efforts to commercialise in the UK have hit a snag.

Dalton Gooding has agreed to stand down as chairman of biotech company Avita Medical but shareholders today supported the re-elect

Perth-based Avita Medical Ltd, formerly Clinical Cell Culture, has posted a 16 per cent increase in unaudited revenue over the 2008 financial year, underpinned by strong growth sales of its respiratory products.

Clinical Cell Culture Ltd has proposed a company name change to Avita Medical Limited, whilst planning to undertake a 1 for 10 share consolidation.

PERTH-BASED burns treatment developer Clinical Cell Culture Ltd, or C3, announced it will close its American offices and sell its CellSpray technology after completing a strategic review of its option

Perth-based burns treatment developer Clinical Cell Culture Ltd, or C3, has announced that lower-than-expected sales and approval delays will keep it from reaching its $5-7 million revenue target for the 2007 financial year.

Perth-based burns treatment developer Clinical Cell Culture Ltd has closed its $10 million share purchase plan oversubscribed, as well as raising $3.8 million in a placement, to raise funds for further growth, the company announced today.

Perth-based burns treatment developer Clinical Cell Culture Ltd, or C3, will raise $10 million through a share purchase plan to existing shareholders for further commercialisation of the company's ReCell product.

Shares in biomedical company Clinical Cell Culture Ltd have surged over 7 per cent today after announcing the Therapeutic Goods Administration has completed its approval process of ReCell®.

Perth-based skins and burns treatment developer Clinical Cell Culture Ltd has announced that it has appointed Bob Atwill as its new chief executive officer and a director of the company.

PERTH-BASED skins and burns treatment developer Clinical Cell Culture Ltd has announced managing director Troels Jordansen will be stepping down, while Professor Fiona Wood has rejoined the board.

Perth-based skins and burns treatment developer Clinical Cell Culture Ltd has announced Managing Director Troels Jordansen will be stepping down from his position as Chief Executive Officer, while Professor Fiona Wood has rejoined the board.

Delays in securing regulatory approvals in the United States and Australia as well as slower than expected product sales have prompted Clinical Cell Culture Ltd to announce staff cuts and postponement of some R&D.

9-Dec-05Response to ASX Query

CLINICAL Cell Culture continues the roll-out of its skin repair products around the world, appointing distributors in Russia and Slovakia.

Clinical Cell Culture Ltd co-founder Dr Fiona Wood is to step down from the board of the company, which is in the midst of commercialising the results of her burns research.

Medical technology company C3 is to retain managing director and CEO Troels Jordansen for two more years, effective from July 1 2005.

Clinical Cell Culture Ltd 30-Aug-05 AMP Ltd ceased to be a substantial shareholder.

CLINICAL Cell Culture’s share price has taken a hammering this week after the company disclosed delays in the commercial introduction of its CellSpray and CellSpray XP products.